GlassScriptPhysician profile
Kaitlyn Wilson
NPI 1508550591
$7,223.60
in general payments reported to CMS, 2019-2025
53 companies · $3,280 in 2025
The $3,280 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $998 · 2024: $2,946 · 2025: $3,280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,677 · Education: $547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,676.68 |
| Education | $546.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $659.35 | 2023-2025 | Tecvayli, Darzalex, Talvey |
| Astrazeneca Pharmaceuticals LP | $644.07 | 2023-2025 | Enhertu, Calquence, Lynparza |
| Incyte Corporation | $478.67 | 2023-2025 | Opzelura, Jakafi, Monjuvi |
| Abbvie INC. | $346.96 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $325.10 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $311.93 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $307.32 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $281.69 | 2023-2025 | Ninlaro, Alunbrig, Fruzaqla |
| Glaxosmithkline, LLC. | $266.85 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Genentech USA, INC. | $266.15 | 2023-2025 | Phesgo, Tecentriq, Polivy |
| Gilead Sciences, INC. | $199.43 | 2023-2025 | Trodelvy |
| Daiichi Sankyo INC. | $183.82 | 2024-2025 | Enhertu, Datroway |
| Lilly USA, LLC | $182.70 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Celgene Corporation | $175.54 | 2023-2025 | Reblozyl, Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $163.47 | 2023-2025 | Opdivo, Opdualag |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $157.83 | 2024-2025 | Cabometyx |
| Sobi, INC | $143.71 | 2023-2025 | |
| Myriad Genetic Laboratories, INC. | $130.08 | 2024 | Myrisk |
| Astellas Pharma US INC | $125.35 | 2023-2025 | Xtandi, Vyloy, Xospata |
| Regeneron Healthcare Solutions, INC. | $124.73 | 2023-2025 | Libtayo |
| Array Biopharma INC | $115.29 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Pharmacosmos Therapeutics INC. | $112.86 | 2024-2025 | Monoferric, Cosela |
| Aveo Pharmaceuticals, INC. | $107.68 | 2023-2025 | Fotivda |
| Genzyme Corporation | $104.42 | 2023-2025 | |
| Tersera Therapeutics LLC | $99.82 | 2023-2025 | Zoladex, Quzyttir |
| Rigel Pharmaceuticals, INC. | $98.62 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
| Eisai INC. | $93.77 | 2024 | |
| Springworks Therapeutics, INC. | $92.71 | 2024-2025 | Ogsiveo |
| Spectrum Pharmaceuticals INC. | $85.55 | 2023-2025 | Rolvedon |
| Ipsen Biopharmaceuticals, INC | $82.96 | 2023-2025 | Onivyde, Tazverik |
| Servier Pharmaceuticals LLC | $69.26 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.02 | 2023-2025 | |
| Genmab U.S., INC. | $62.93 | 2024-2025 | Tivdak |
| Stemline Therapeutics INC. | $56.39 | 2023-2025 | Orserdu |
| Apellis Pharmaceuticals, INC. | $54.61 | 2023-2024 | Empaveli |
| Legend Biotech USA INC. | $42.45 | 2025 | Carvykti |
| Geron Corporation | $40.45 | 2025 | Rytelo |
| Jazz Pharmaceuticals INC. | $40.41 | 2024-2025 | |
| Novocure INC. | $40.23 | 2025 | Optune Lua (Novottf-200t) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.94 | 2025 | |
| Iovance Biotherapeutics, INC. | $28.27 | 2025 | Amtagvi |
| Fresenius Kabi USA, LLC | $22.75 | 2024 | Stimufend |
| Dendreon Pharmaceuticals LLC | $20.53 | 2025 | Provenge |
| Sun Pharmaceutical Industries INC. | $19.72 | 2023 | Yonsa, Odomzo |
| Blue Earth Diagnostics | $19.66 | 2024 | |
| Seagen INC. | $19.33 | 2023 | Adcetris |
| Caris Mpi, INC. | $19.07 | 2025 | Mi Cancer Seek |
| Mirati Therapeutics, INC. | $17.92 | 2023 | Krazati |
| Amgen INC. | $17.71 | 2023 | Blincyto, Kyprolis |
| Acrotech Biopharma INC. | $17.56 | 2024 | Beleodaq |
| Immunocore Limited | $16.72 | 2025 | Kimmtrak |
| Agios Pharmaceuticals, INC. | $14.95 | 2024 | |
| Alexion Pharmaceuticals, INC. | $14.29 | 2024 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaitlyn Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.